You are currently viewing a new version of our website. To view the old version click .

Livers, Volume 1, Issue 3

September 2021 - 5 articles

Cover Story: The gut microbiome has evolved as a major player in liver disease pathogenesis and progression. Targeting the intricate elements of the gut–liver axis, the hepatic immune response and relevant associated signaling pathways may offer opportunities for novel anti-fibrotic drug discovery. Our review discusses established and emerging therapeutic strategies fueling clinical drug development pipeline, translated from our current knowledge of the gut–liver axis. We outline therapies targeted at amelioration of hepatic fibrosis and rising portal hypertension that characterize and define the course of decompensated cirrhosis. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (5)

  • Review
  • Open Access
9 Citations
11,613 Views
33 Pages

9 September 2021

Antifibrotic therapies for the treatment of liver fibrosis represent an unconquered area of drug development. The significant involvement of the gut microbiota as a driving force in a multitude of liver disease, be it pathogenesis or fibrotic progres...

  • Technical Note
  • Open Access
4 Citations
3,762 Views
9 Pages

Assisting Difficult Liver Operations Using 3D Printed Models

  • Andreas Tooulias,
  • Georgios Tsoulfas,
  • Vasileios Papadopoulos,
  • Maria Alexiou,
  • Ion-Anastasios Karolos,
  • Christos Pikridas and
  • Vassilios Tsioukas

1 September 2021

Liver cancer is estimated to be the fifth most common in the world, while it is also considered the third leading cause of cancer death. In cases of primary liver cancer, surgery in combination with chemotherapy and radiotherapy can lead to a complet...

  • Case Report
  • Open Access
4 Citations
4,326 Views
6 Pages

Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature

  • Emanuele Palomba,
  • Marco Maggioni,
  • Giulia Viero,
  • Davide Mangioni,
  • Rosa Lombardi,
  • Barbara Antonelli,
  • Daniele Dondossola,
  • Massimo Iavarone,
  • Anna Ludovica Fracanzani and
  • Alessandra Bandera
  • + 2 authors

19 August 2021

Rare liver diseases caused by ductal plate malformation, such as congenital hepatic fibrosis (CHF), Caroli syndrome, and polycystic liver disease, can have clinical manifestations such as recurrent cholangitis—frequently involving multidrug-resistant...

  • Article
  • Open Access
4 Citations
3,443 Views
16 Pages

27 July 2021

Hepatic steatosis is a consequence of distorted lipid storage and plays a vital role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). This study aimed to explore the role of the COP9 signalosome (CSN) in the development of hepatic ste...

  • Review
  • Open Access
24 Citations
5,472 Views
14 Pages

Mitochondrial Dynamics in Drug-Induced Liver Injury

  • Anup Ramachandran,
  • David S. Umbaugh and
  • Hartmut Jaeschke

23 June 2021

Mitochondria have been studied for decades from the standpoint of metabolism and ATP generation. However, in recent years mitochondrial dynamics and its influence on bioenergetics and cellular homeostasis is also being appreciated. Mitochondria under...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Livers - ISSN 2673-4389Creative Common CC BY license